Considering other settlements, limited build-up of sales over FY23-26E, and unlimited quantities of g-Revlimid by Cipla post Jan-26E, there could be a potential NPV addition of `40 per share from this opportunity. We await clarity on further details of the agreement.
from The Financial Express https://ift.tt/2WgbNxW
https://ift.tt/eA8V8J Motilal Oswal
from The Financial Express https://ift.tt/2WgbNxW
https://ift.tt/eA8V8J Motilal Oswal
Comments
Post a Comment